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Background: Thymosin beta 10 (Tbeta10) overexpression has been reported in a variety of human cancers. However,
the role of Tbeta10 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to analyze
Tbeta10 expression in tumor and matched non-tumorous tissues, and to assess its prognostic significance for HCC after
hepatectomy.
Methods: The level of Tbeta10 mRNA and protein in tumor and matched non-tumorous tissues was evaluated in 26
fresh HCC cases by reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Additionally, Tbeta10
protein expression in 196 HCC was analyzed by immunohistochemistry (IHC) and correlated with clinicopathological
characteristics and survival.
Results: Results from RT-PCR and western blot analysis show that the levels of Tbeta10 mRNA and protein were
significantly higher in tumor tissues of HCC, compared to that in matched non-tumorous tissues (P = 0.01 and
P <0.001, respectively). IHC staining showed that high expression of Tbeta10 was detected in 58.2% (114/196) of
HCC cases. High expression of Tbeta10 was significantly associated with advanced TNM stage (P <0.001). Survival
analysis demonstrated that high Tbeta10 was related to shorter overall survival (OS) (P = 0.000) and disease-free
survival (DFS) (P = 0.000). Multivariate analysis showed that high expression of Tbeta10 was an independent prognostic
factor for both OS (P = 0.001, HR = 4.135, 95% CI: 2.603 to 6.569) and DFS (P = 0.001, HR = 2.021, 95% CI: 1.442 to 2.832).
Subgroup analysis revealed that high expression of Tbeta10 predicts poorer survival for early and advanced stage.
Conclusions: Tbeta10 protein abnormal expression might contribute to the malignant progression of HCC. High
expression of Tbeta10 predicts poor prognosis in patients with HCC after hepatectomy.
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Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third leading cause of cancer mortality
worldwide [1]. Liver resection remains the curative option
for HCC with a 5-year overall survival (OS) rate of 50
to 70% after curative hepatectomy, but the postoperative
recurrence rate remains as high as 70 to 83.7% [2]. Unfor-
tunately, at present, there are no accurate prognostic* Correspondence: xiajch@sysucc.org.cn; Chminsh@mail.sysu.edu.cn
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reproduction in any medium, provided the orfactors to predict prognosis of HCC patients on the
basis of commonly used clinicopathological characteristics
[3]. Therefore, it is critical to identify more effective prog-
nostic factors for patients with HCC after hepatectomy.
Thymosin beta 10 (Tbeta10) is a naturally occurring
peptide that was first isolated, along with other lympho-
cytopoietic factors, in 1966 by Goldstein et al. from the
calf thymus [4]. Tbeta10 is a member of the β-thymosin
family, which is widely distributed in many tissues, with
proven biological activities as an actin-sequestering protein
involved in cell motility. In recent years, Tbeta10 has been
proposed as a multifunctional regenerative peptide [5] that
is involved in many critical biological activities including
cell proliferation, anti-apoptosis and angiogenesis [6-8]. Intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Correlations between Tbeta10 expression and










≤50 119 69 0.949
>50 77 32 45
Gender
Male 162 68 194 0.932
Female 34 14 20
HBV infection
Absent 23 10 13 0.865
Present 173 72 101
AFP level
≤25 ng/ml 61 30 31 0.161
>25 ng/ml 135 52 83
Liver cirrhosis
Absent 55 25 30 0.521
Present 141 57 84
Tumor size (cm)
≤5 cm 80 37 43 0.298
>5 cm 116 45 71
Tumor number
Single 163 73 90 0.063
2 to 3 33 9 24
TNM stage
I to II 146 72 74 <0.001
III 50 10 40
Tumor
differentiation
I to II 100 44 56 0.531
III to IV 96 38 58
Vascular
invasion
Absent 167 74 93 0.092
Present 29 8 21
AFP, alpha fetoprotein; HBV, hepatitis B virus; Tbeta10, thymosin beta 10.
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levels of Tbeta10 expression have been found in the
metastatic tumor of thyroid [9,10], and cutaneous malig-
nancy [11], while low levels of Tbeta10 expression have
been associated with metastatic cervical carcinoma [12].
More recently, the expression features of Tbeta10 and
Tbeta4 was reported by Theunissen et al. [13], but Tbe-
ta10’s relationship with clinicopathological characteristics
and survival are still unknown. Thus, the aim of the
present study was to evaluate the expression of Tbeta10
in tumor tissues of HCC and to assess its prognostic
significance in HCC patients after hepatectomy.
Methods
Ethics statement
The research was approved by the institutional review
board (IRB) of Sun Yat-sen University Cancer Center, and
written informed consent was obtained from each patient
involved in the study.
Patients and tumor tissue samples
To detect the mRNA and protein level of Tbeta10 in
HCC, fresh tumor and the matched adjacent non-
tumorous tissues were collected from 26 patients with
HCC who underwent hepatectomy between October 2012
and December 2012 in our department, the Department
of Hepatobiliary Surgery, Cancer Center of Sun Yat-Sen
University (Guangzhou, China).
A cohort of 196 consecutive patients who received
hepatectomy for HCC in our department from January
2004 to December 2006 was enrolled. The including cri-
teria for the present study were (1) no previous treatment
for HCC before surgery, (2) histologic confirmation of
HCC, (3) R0 resection, (4) no lymph node or extrahepatic
metastasis, and (5) a follow-up period of ≥3.0 months.
The main clinical and pathological variables of all patients
were described in detail in Table 1. In brief, there were 162
male and 34 female patients, with a median age of 47-years
old (mean ± SD: 47.1 ± 12.3, range: 15 to 78). Tumor size
ranged from 1.3 cm to 24.0 cm (mean ± SD: 7.3 ± 4.0), 80
patients (40.8%) had a tumor ≤5.0 cm, and 116 (59.2%)
had a tumor >5.0 cm. A total of 163 patients (83.2%)
had a single tumor, and 33 (16.8%) had 2 to 3 tumors.
Of the cohort, 173 patients (88.3%) had hepatitis B virus
(HBV) infection, and only 2 patients had hepatitis C virus
(HCV) infection. According to the 7th edition tumor-
node-metastasis (TNM) classification of the American
Joint Committee on Cancer (AJCC) [14], 129 patients
(65.8%) had stage I disease, 17 (8.7%) had stage II disease,
and 50 (25.5%) had stage III disease (Table 1).
RNA preparation and protein extraction
Total RNA was extracted by using Trizol solution
(Invitrogen, Shanghai, China) according to manufacturerinstructions. Total protein was extracted with RIPA buffer
(Beyotime, Shanghai, China) according to the manufac-
turer’s instruction. RNA and protein samples were stored
at -80°C until use.Real-time quantitative reverse transcription-polymerase
chain reaction
To quantify the mRNA expression of Tbeta10, real-time
PCR amplification was undertaken with a Bio-Rad CFX96
Real-time PCR System (Life Technologies, Carlsbad, CA,
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were as follows: Tbeta10, sense: 5’-TGGCAGACAAAC
CAGACATGG-3’, and antisense: 5’-CGAAGAGGACG
GGGGTAGG-3’ and GAPDH, sense: 5’-CTCCTCCTGT
TCGACAGTCAGC-3’, antisense: 5’-CCCAATACGACC
AAATCCGTT-3’. The reactions were performed in a final
volume of 15 μL, consisting of 7.5 μL of 2× SYBR Green
master mix (Invitrogen), 2-μL of each 5’- and 3’- primer
(1.5 pmol/μL), 0.5 μL of the sample cDNA, and 5 μL
water. The amplification was performed as follows: 95°C
for 10 min, one cycle, followed by 95°C for 30 s and
60°C for 60 s, 45 cycles. The relative expression levels
of thymosin-10 were normalized to that of the internal
control gene, GAPDH. Data were analyzed using the
comparative threshold cycle (2- -ΔΔCT) method.Western blotting
The HCC samples including tumor and non-tumorous
tissues were lysed in RIPA lysis buffer. Lysates were
harvested by centrifugation (12,000 rpm for 30 min at 4°C.
Protein samples (30 μg) were resolved in 12% sodium
dodecyl sulfate polyacrylamide gel for electrophoresis
and transferred to a polyvinylidene difluoride (PVDF)
membrane. After blocking nonspecific binding sites for
60 min with 8% nonfat milk, membranes were incu-
bated overnight at 4°C with a rabbit antibody against
Tbeta10 (1:1,000 dilution; Abcam, Cambridge, UK) or
GAPDH (1:10,000 dilution; Abcam, Cambridge, UK).
Membranes were washed four times with TRIS-buffered
saline with Tween-20 for 10 min. After being washed,
membranes were probed with HRP-conjugated second-
ary antibody and visualized using a chemiluminescent
system (Cell Signaling Technology, Danvers, MA, USA).
Band intensity was measured by Quantity One software
(BioRad, Hercules, CA, USA).Immunohistochemistry
Isolated tumors were fixed in 10% neutral buffered for-
malin for 48 h and embedded in paraffin according to
standard protocols. Sections (thickness, 2 μm) were
deparaffinized and rehydrated in a graded series of 100%,
95%, 90%, 80% and 70% ethanol. For antigen retrieval,
slides were boiled in EDTA (1 mM, pH 8.0) for 15 min in
a microwave oven. Endogenous peroxidase activity was
blocked in 3% H2O2 at room temperature for 10 min.
Sections were then stained with anti-Tbeta10 (rabbit
anti-Tbeta10 monoclonal antibody; 1:500 dilution; Abcam,
Cambridge, UK) antibodies at 4°C overnight. After three
washes in PBS, sections were incubated with horserad-
ish peroxidase (HRP)-conjugated secondary antibody
(Envision Detection kit, GK500705, Gene Tech, Shanghai,
China) for 30 min at room temperature. After washing
in PBS, antibody complexes were colored with 3,3’-diaminobenzidine (DAB ) and then counterstained with
hematoxylin. Slides were dehydrated and evaluated.
Immunohistochemistry evaluation
The specimens were analyzed by two pathologists who
were blinded to the patients’ clinical outcomes. The total
Tbeta10 immunostaining score was calculated as the sum
of the positively stained tumor cells and staining intensity.
Briefly, the percentage of positive staining was scored
as ‘0’ (0 to 9%, negative), ‘1’ (10 to 25%, sporadic), ‘2’ (26
to 50%, focal), or ‘3’ (>50%, diffuse). The staining inten-
sity was scored as ‘0’ (no staining), ‘1’ (weak staining), ‘2’
(moderate staining), or ‘3’ (strong staining). The total
immunostaining score was calculated as the value of
percent positivity score × staining intensity score, and
ranged from 0 to 9. The expression level of Tbeta10
was defined as follows: ‘-’ (score 0 to 1), ‘+’ (2 to 3), ‘++’
(4 to 6) and ‘+++’ (>6). Based on their levels of Tbeta10
expression, patients were divided into two groups: low
Tbeta10 (‘-’ and ‘+’) and high Tbeta10 (‘++’ and ‘+++’).
Follow-up
Follow-up of patients included physical examination,
routine laboratory testing, and contrast-enhanced abdom-
inal computed tomography (CT) every 3 months in the
first 2 years, every 6 months in the 3 to 5 years after
surgery, and then every year thereafter. At each follow-
up visit, liver function tests and AFP were determined.
Chest radiography was done every 6 months to observe
lung metastasis. If necessary, CT of the chest, bone
scintigraphy and positron emission tomography (PET)
were also performed for the diagnosis of metastasis
and/or recurrence. The last follow-up date for patients
still alive was November 2013.
Causes of death and sites of recurrence were determined
from death certificates, medical interviews, and radio-
logical findings. Overall survival (OS) was defined as the
interval between the time of hepatectomy to death or
to the last date of follow-up. Disease-free survival
(DFS) time was between the time of hepatectomy and
the time when recurrence was diagnosed or to the time
of the last follow-up. The treatment for recurrent tumor
was determined by our multidisciplinary team (MDT)
including surgeons, oncologists, radiologists, gastroen-
terologists, and pathologists.
Statistical analysis
The statistical analyses were performed using the SPSS
13.0 statistical software (SPSS Company, Chicago, Illinois,
USA). Comparisons between two groups were done using
Student’s t-test for continuous data and the Chi square
test for categorical data. The correlation between the
Tbeta10 expression and clinicopathologic characteristics































Figure 1 The mRNA and protein expression of Tbeta10 was significantly higher in hepatocellular carcinoma (HCC) tumor than in matched
non-tumorous tissues. (A) The mRNA expression of Tbeta10 in human HCC specimens was evaluated by real-time quantitative PCR. The relative mRNA
expression of Tbeta10 was significantly higher in 26 HCC tumor tissues than in matched non-tumorous tissues (P = 0.01). Horizontal lines represent the
mean. (B) Relative Tbeta10 protein expression levels in 24 HCC tumor tissues and matched non-tumorous tissues (Tbeta10/GAPDH, P = 0.0005) were
detected by western blot. Horizontal lines represent the mean. (C) Representative result of Tbeta10 protein expression in four paired HCC tumor tissues
and the matched non-tumorous tissues (T, hepatocellular carcinoma tumor tissues; N, matched non-tumorous tissues).




Figure 2 Representative immunohistochemical staining of
Tbeta10 in tumorous and non-tumorous tissues. (A) Normal liver
tissue distant from the tumor, scored Tbeta10 (-), (B) Low expression
of Tbeta10 in non-tumorous tissue, scored Tbeta10 (‘-’ and ‘+’);
(C) High expression of Tbeta10 in tumor tissue, scored Tbeta10
(‘++’ and ‘+++’). (A-C with 400 ×magnification).
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by log-rank test. The prognostic varieties in predicting
OS and DFS were assessed by multivariate Cox propor-
tional hazards regression analysis. Results were given as
mean ± S.D. All statistical tests were two-sided, and a
significant difference was considered when P <0.05.
Results
Tbeta10 mRNA and protein expression in hepatocellular
carcinoma tissues
The mRNA level of Tbeta10 was determined by real-time
quantitative RT-PCR assays in 26 fresh tumor and the
matched adjacent normal tissues. The Tbeta10 expression
level was significantly higher in 19 (73.08%) tumor tissues
compared to the adjacent non-tumorous tissues (P = 0.01,
Figure 1A). The protein level of Tbeta10 was also evalu-
ated by western blotting in 24 HCC tissues. As shown in
Figure 1B, consistent with the results of the real-time
quantitative RT-PCR, the protein expression of Tbeta10
was significantly higher in 18 (75%) tumor tissues, com-
pared to that in adjacent non-tumorous tissue (P <0.001).
Immunohistochemical analysis of Tbeta10 expression in
hepatocellular carcinoma specimens and Tbeta10’s
relationship with the clinicopathological parameters
Tbeta10 expression was investigated in 196 HCC paraffin-
embedded tissues of surgical specimens using IHC stain-
ing. As it was shown in Figure 2, Tbeta10 immunostaining
was predominantly observed in the cytoplasm of carcin-
oma cell and rarely in nucleus. Among these 196 HCC
cases, 114 (58.2%) showed high Tbeta10 expression,
and 82 (41.8%) showed low Tbeta10 expression. The
correlations between Tbeta10 expression level and clin-
icopathological features were shown in Table 1. Tbeta10
expression was significantly correlated with advanced
TNM stage (P <0.001). However, no significant relation-
ship was found between Tbeta10 expression and gender,
age, HBV infection, alpha fetoprotein (AFP) level, under-
lying liver cirrhosis, tumor differentiation, tumor size,
tumor number and vascular invasion (Table 1).
The relationship of Tbeta10 expression and the survival
of hepatocellular carcinoma patients
The mean follow-up period was 47.5 ± 35.0 months
(range 3.0 to 110.7 months). At the end of follow-up,
there were 108 deaths and 88 survivals. The 1, 3, and
5-year OS of the whole group was 82%, 60% and 46%,
respectively. Univariate analysis showed that the OS was
directly influenced by underlying liver cirrhosis (P = 0.026),
tumor size (P = 0.024), tumor number (P = 0.042), TNM
stage (P <0.001), tumor differentiation (P = 0.018), vascular
invasion (P <0.001), and expression of Tbeta10 (P <0.001).
Factors not significantly affecting OS included age, gender,
HBV infection, and AFP level. Multivariate analysis showedthat expression of Tbeta10 (P <0.001, HR = 4.135; 95% CI:
2.603-6.569), vascular invasion (P = 0.002, HR = 2.051; 95%
CI: 1.288-3.264) and TNM stage (P = 0.018, HR =1.649;
95% CI: 1.091-2.492) were independent prognostic factors
for OS (Table 2). The 1, 3, and 5-year OS for patients with
Table 2 Univariate and multivariate analyses of overall and





P value HR (95% CI) P value
Overall survival
Age (≤50 y versus >50 y) 0.429































Age (≤55 y versus >55 y) 0.523





























Tbeta10 (low versus high) <0.001 2.021
(1.442 to 2.832)
0.001
AFP, alpha fetoprotein; HBV, hepatitis B virus; HR, hazard ratio; Tbeta10,
thymosin beta 10.
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ively, and 93%, 88%, and 77%, respectively, for patients with
Tbeta10 low expression (P <0.001, Figure 3A).The 1-, 3-, and 5-year DFS of the whole group was
48%, 29% and 24%, respectively. Univariate analysis
showed that HBV (P = 0.009), tumor size (P = 0.006),
tumor number (P = 0.018), TNM stage (P <0.001), tumor
differentiation (P = 0.003), vascular invasion (P <0.001) and
expression of Tbeta10 (P <0.001) were prognostic factors of
DFS. Multivariate analysis indicated that expression of
Tbeta10 (P = 0.001, HR = 2.021; 95% CI: 1.442 to 2.832),
tumor size (P = 0.027, HR = 1.483; 95% CI: 1.047 to 2.100),
vascular invasion (P = 0.001, HR = 2.082; 95% CI: 1.387 to
3.145) and TNM stage (P = 0.023, HR =1.537; 95% CI:
1.060 to 2.228) were independent prognostic factors of DFS
(Table 2). The 1-, 3-, and 5-year DFS for patients with
Tbeta10 high expression were 36%, 18%, and 14% respect-
ively, and 65%, 44%, and 37% respectively, for patients with
Tbeta10 low expression (P = 0.000, Figure 3B).
Furthermore, the correlation of Tbeta10 expression with
survival was analyzed according to TNM stage. For 146
patients with TNM stage I and II disease after curative
resection, the 1-, 3-, and 5-year OS for patients with
Tbeta10 high expression was 76%, 48%, and 29%, respect-
ively, and 93%, 89%, and 78%, respectively, for patients with
Tbeta10 low expression (P <0.001), the corresponding DFS
was 42%, 27%, and 20%, respectively, and 65%,46%, and
38%, respectively (P = 0.003). For 50 patients with TNM
stage III disease, the 1-, 3-, and 5-year OS for patients with
Tbeta10 high expression was 72%, 24%, and 11%, respect-
ively, and 90%, 80%, and 70%, respectively, for patients with
Tbeta10 low expression (P = 0.001), the corresponding DFS
was 60%, 30%, and 30%, respectively, and 24%, 3%, and 3%,
respectively (P = 0.011, Figure 4).
Discussion
In the present study, we demonstrated that the expression
of Tbeta10 was significantly higher in HCC tissue, com-
pared to that in non-tumorous liver tissue, high expression
of Tbeta10 was significantly associated with advanced
TNM stage, and for the first time, we revealed that high
expression of Tbeta10 predicted poorer survival for patients
with HCC after hepatectomy, even in patients subgrouped
according to TNM stage.
There has been increasing interest in the role of
Tbeta10 in human cancers in recent years. Tbeta10 has
been shown to be aberrantly expressed in many cancer
types. IHC staining performed on HCC, human melanoma,
renal cell carcinoma, gastric, breast, lung, and thyroid
cancers showed strong positive staining of Tbeta10 spe-
cifically in tumor tissues compared with weak staining
in the surrounding non-tumorous tissues [11,13,15-19].
Similarly, several reports have shown the correlation of
Tbeta10 expression level with progression and metastasis
as well as poor patient outcome [9,15]. Unlike its proposed
oncogenic role, Tbeta10 has been found to be downregu-
lated in human ovarian cancer [7], and low expression
AB
Figure 3 Overall and recurrence-free survival curves of 196 hepatocellular carcinoma (HCC) cases after hepatectomy assessed by
Kaplan-Meier analysis according to Tbeta10 expression. Patients with high expression of Tbeta10 were significantly associated with poorer
overall survival (A, P = 0.000) and disease-free survival (B, P = 0.000).
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cholangiocarcinoma in vitro and in vivo [20]. There are
contradicting findings regarding Tbeta10 expression in
ovarian and lung cancers [21-24]. In HCC the higher
incidence of Tbeta10 IHC reactivity was found in tumor
cells involved in stromal invasion, indicating a possible
major role for Tbeta10 in HCC progression [13]. In the
present study, we conducted RT-PCR, western blot and
IHC to detect the expression of Tbeta10 in tumor and thematched adjacent non-tumorous tissues. Our results show
that the expression of Tbeta10 was significantly higher in
tumor tissues than that in non-tumorous tissues, which
indicated that Tbeta10 might play an important part in
the carcinogenesis of HCC.
Tbeta10, as a member of the β-thymosin family, is the
main intracellular G actin-sequestering protein involved
in cell proliferation, migration, and differentiation [6-8].
Many reports described the potential functional roles of
AB
Figure 4 Overall and disease-free survival curves assessed by Kaplan-Meier analysis according to Tbeta10 expression and TNM stage.
(A) Overall survival. High expression of Tbeta10 predicted poorer overall survival (OS) not only for early TNM stage (TNM stage I to II, group 1
versus group 2; P = 0.001), but also for advanced TNM stage (TNM stage III, group 3 versus group 4; P <0.001). (B) Disease-free survival. High
expression of Tbeta10 predicts poor DFS for both early TNM stage (group 1 versus group 2; P = 0.003) and advanced TNM stage (group 3 versus
group 4; P = 0.011). Group 1, early TNM stage/Tbeta10 low expression (n = 72); group 2, early TNM stage/Tbeta10 high expression (n = 74); group
3, advanced TNM stage/Tbeta10 low expression (n = 10); group 4, advanced TNM stage/Tbeta10 high expression (n = 40).
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are quite different among different types of cancers.
Tbeta10 inhibits tumor growth, angiogenesis, migration,and invasion of ovarian cancer both in in vitro and in vivo
studies by disrupting actin polymerization and by inhi-
biting Ras action [20,25]. In pancreatic cancer, Tbeta10
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leukin (IL-7) and IL-8, which may promote pancreatic
cancer pathogenesis and progression [26]. Studies on
thyroid carcinoma, melanoma, non-small cell lung cancer
and some other malignant tumors [21,27,28] also show
that Tbeta10 possesses tumor progression properties. In
the present study, we demonstrated that high expression
of Tbeta10 was associated with advanced TNM stage. It
indicated that overexpression of Tbeta10 was associated
with tumor growth and invasion in HCC.
Hepatectomy remains the most effective curative therapy
and provides better survival outcomes for patients with
HCC. Unfortunately, approximately 33% of HCC patients
die within the first year even after curative surgery, mainly
because of tumor recurrence and spread [29,30]. Currently,
prognostic evaluation is mainly based on tumor stage and
histopathologic observation such as tumor size, tumor
number, and vascular invasion [1-3]. However, we found
that although patients have modest tumor presentation, the
prediction for patients’ overall and disease-free survival can
be variable and inaccurate. Recent studies have suggested
some factors, such as molecular and cellular characteristics
of primary tumor, may improve our ability to prognosticate
[4]. In the present study, the expression of Tbeta10 was
revealed as an independent prognostic factor for both OS
and RFS for patients with HCC after hepatectomy. The
patients with high expression of Tbeta10 had a shorter OS
and RFS. More importantly, subgroup analysis showed the
expression of Tbeta10 was significantly associated with
poor prognosis not only in patients with early TNM stage
undergoing curative resection, but also in patients with
advanced TNM stage undergoing palliative resection. It
might indicate that Tbeta10 is one of the reliable clinical
predictors for outcome of individual patients with HCC
undergoing hepatectomy. However, prospective clinical
studies are needed to confirm that.
There were some limitations in the present study that
require comment. First, it was a retrospective analysis from
a single institution with small sample size, and second
patient population is biased due to high prevalence of HBV
infection (88.3%). Whether these results can be applied to
Western populations wherein HCV, and other etiologies
of liver disease predominate, requires further study and
comment. Therefore, a large-scale prospective validation
study is needed to confirm the results.
Conclusions
In conclusion, our study revealed that Tbeta10 is an in-
dependent prognostic factor for OS and DFS in patients
with HCC after hepatectomy. High expression of Tbeta10
in tumor is correlated with advanced TNM stage. How-
ever these results, which are based on a Chinese cohort
(mostly associated with HBV infections), should be further
confirmed in other populations of patients with HCC.Abbreviations
AFP: alpha fetoprotein; CT: computed tomography; DFS: disease-free survival;
HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma;
IHC: immunohistochemistry; MDT: multidisciplinary team; OS: overall survival;
PET: positron emission tomography; RT-PCR: reverse transcription-polymerase
chain reaction.
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